Home Companies Catalysts Deep Dives
ACCG-2671 ACCG-2671 PHASE1
Drug Profile
ModalitySmall molecule
RouteORAL
Therapy AreaCVRM
Formulations[{"id":"accg-oral-1","route":"ORAL","device":"Tablet","setting":"PATIENT_SELF","duration":null,"freq
Companies
GPCR (ORIGINATOR)100%
Mechanism: Dual amylin/calcitonin receptor agonist
Expert: Dual agonist targeting both amylin and calcitonin receptors, potentially providing enhanced metabolic effects through complementary receptor activation.
Everyday: A pill that activates two related hormone receptors to promote weight loss while protecting muscle and bone.
Targets: ["AMYLIN","CALCITONIN"]
Programs (1)
IndicationStageKey StudyRegional Status
ObesityPHASE1Phase 1 SAD/MAD[]
Upcoming Catalysts (1)
ACCG-2671 - Obesity (Amylin) - Ph1 - Data H2 2026
Notes
Next-gen obesity backbone. Dual Amylin and Calcitonin Receptor Agonist (DACRA). Preclinical showed superior weight loss in combination with semaglutide. Potential for muscle-sparing weight loss. Phase 1 initiated Dec 2025.
Data from Supabase · Updated 2026-03-24